Skip to content

Microdosing

The practice of taking sub-perceptual doses of psychedelics, and the evidence on whether measurable effects follow.

State of the evidence

Synthesized

Synthesized from 18 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Microdosing, micro-dosing, sub-perceptual dosing, low-dose psychedelics, then ranked by relevance.

The evidence on psychedelic microdosing is mixed and inconclusive. While observational and survey studies report subjective improvements in mood, cognition, and well-being, the few placebo-controlled trials find that these benefits are largely explained by the placebo effect and positive expectancy. The most rigorous meta-analyses show no significant mood benefits and a small decrease in cognitive control, indicating that any positive effects are not robustly supported by controlled research.

Confidence in the evidence

Low-Moderate
  • Only three placebo-controlled trials (article_ids 15941, 19853, 17432) exist, with small to moderate sample sizes (34–191 participants), and all show no significant between-group differences or attribute benefits to expectancy.
  • Observational and survey studies (e.g., 17070, 25833, 25830) are large but highly susceptible to bias, including self-selection, lack of blinding, and subjective reporting.
  • The umbrella review (27669) synthesizing three meta-analyses found only a small negative effect on cognitive control and no significant mood effects, with high primary-study overlap and methodological heterogeneity.
  • Preclinical evidence (27727) in rats shows no behavioral or neurogenic effects, and the systematic review (25852) notes that claims of expectancy-driven effects are premature.
  • Overall, the evidence is dominated by low-quality designs, inconsistent findings, and unresolved placebo confounds.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Self-blinding citizen science to explore psychedelic microdosing. 2021
No effect

All psychological outcomes improved from baseline in both microdose and placebo groups, with no significant between-group differences, suggesting anecdotal benefits are due to placebo.

RCT (self-blinding citizen science) Sample size: 191

Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting 2018
Supports

Provided quantitative support for cognitive-enhancing properties of microdosing, but authors caution that future placebo-controlled designs are needed to confirm preliminary findings.

observational (open-label natural setting)

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing 2021
Mixed

Found increased well-being and reduced anxiety/depression at 4 weeks, but positive expectancy at baseline predicted improvements, indicating a significant placebo response.

prospective observational Sample size: 81

Motives and Side-Effects of Microdosing With Psychedelics Among Users 2019
Supports

Performance enhancement was the main motive (37%), and most reported negative effects were psychological and acute; majority were unaware of exact dose consumed.

observational (online survey) Sample size: 1116

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study 2022
No effect

Acute effects were more intense for active dose only in participants who correctly identified their condition; no effects on creativity or cognition, with small changes toward cognitive impairment.

RCT (double-blind placebo-controlled) Sample size: 34

Psychedelic microdosing benefits and challenges: an empirical codebook 2019
Unclear

Summarized experiences from the microdosing community to identify high-potential targets for future research, without quantitative effect estimates.

qualitative (mixed-methods codebook)

Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. 2019
Supports

Reported improvements in negative moods (especially depression), positive moods, energy, work effectiveness, and health habits; also alleviation of symptoms in various conditions.

observational (descriptive reports) Sample size: 1000

Psychedelic Microdosing: A Subreddit Analysis 2019
Mixed

Motivations included mental health self-management and cognitive enhancement; benefits reported included improved mood and creativity, but limitations included adverse effects, lack of improvement, and concerns about dependence.

observational (content analysis of Reddit)

Psychedelic Microdosing: Prevalence and Subjective Effects 2020
Supports

Microdosers attributed improvements in mood, anxiety, memory, attention, and sociability; common reasons for quitting were legal risks and difficulty obtaining substances.

observational (online survey) Sample size: 2347

The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field 2022
Mixed

Studies showed wide risk of bias; laboratory studies found changes in pain perception, time perception, and neurophysiology; self-report studies found changes in cognition and mental health; claims that effects are largely due to expectancy are premature.

systematic review

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis 2026
No effect

The only significant pooled effect was a small decrease in cognitive control (d = -0.34); all other domains (including mood) were non-significant, with narrative evidence suggesting self-reported mood benefits are likely expectancy-driven.

umbrella review with narrative synthesis Sample size: 1614

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States 2026
Mixed

26.5% of lifetime psychedelic users had microdosed; microdosing was associated with more anxiety symptoms and adverse childhood events, and motives varied by demographics and mental health.

observational (cross-sectional survey)

Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use 2026
Unclear

Argues that microdosing is not a single phenomenon and must be classified by substance class, dose-response, and evidence level; no quantitative effect estimates provided.

review (conceptual and comparative)

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series 2026
Supports

Clinical improvements were observed following an integrative iboga microdosing protocol with psychotherapy, but the design precludes causal inference.

case series Sample size: 3

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey. 2026
Unclear

Provided prevalence data on microdosing for psilocybin, LSD, and MDMA; no effect estimates reported.

observational (nationally representative survey)

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026
No effect

Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, novelty seeking, or dentate gyrus cell proliferation.

preclinical (animal study)

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT 2026
No effect

Psilocybin microdosing was associated with subtle EEG changes (reduced global field power, frequency-specific alterations) but no significant broadband spatiotemporal changes, indicating limited brain effects.

observational (EEG study)

A New Use for an Old Compound: Microdosing LSD to Reduce Fibromyalgia Symptoms 2026
Supports

Microdosed LSD improved pain-related behaviors and facial expressions in a sex- and route-dependent manner in a mouse model of fibromyalgia.

preclinical (animal study)

Points of agreement

  • Observational and survey studies consistently report subjective improvements in mood, well-being, and cognition from microdosing.
  • Placebo-controlled trials consistently find no significant differences between microdose and placebo groups on most outcomes.
  • Positive expectancy and placebo effects are consistently identified as major confounds across multiple study designs.
  • The most rigorous meta-analyses find no significant mood benefits and a small negative effect on cognitive control.

Conflicts

  • Observational studies report positive effects on mood and cognition, while placebo-controlled RCTs find null or expectancy-driven effects.
  • Some studies (e.g., 16309, 25833) report broad benefits, whereas others (e.g., 19853, 27727) find no effects or slight impairment.
  • The systematic review (25852) argues that expectancy explanations are premature, while the umbrella review (27669) and RCTs (15941, 17432) emphasize placebo/expectancy as the primary driver.

Gaps

  • Durability of effects beyond 4 weeks is not studied in controlled designs.
  • Blinding integrity is rarely assessed and often broken, confounding results.
  • Dose standardization and substance purity are lacking in most naturalistic studies.
  • Representative population samples are missing; most studies rely on self-selected, online convenience samples.
  • Preclinical evidence is limited and does not support behavioral or neurogenic effects.
  • No large, multi-site, fully blinded RCTs with adequate sample sizes have been conducted.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Microdosing, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Microdosing or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

447 articles · 174 from the last two years · 87,653 participants across 167 studies reporting sample size

Common study designs

review 82 case study 18 qualitative study 19 cross-sectional survey 20 randomized controlled trial 37

Research

Synthesize the evidence → Search all →

Rational design, synthesis, and characterization of a solid Δ9-tetrahydrocannabinol (THC) nanoformulation suitable for “microdosing” applications

Abhinandan Banerjee, William Hosie, Ana Carolina Terso Ventura et al.

A THC-loaded nanoemulsion was created using an ethanol-assisted method without specialized equipment, producing lipid droplets averaging 190 nm. The nanoemulsion remained colloidally stable for at least six weeks, with no significant loss of cannabinoid potency. It withstood heat, freeze/thaw cycles, carbonation, dilution, high sucrose, and a pH range of 5-8. The nanoemulsion was converted into a water-soluble powder via lyophilization and ball-milling, suitable for microdosing applications. The powder was freely redispersible in water without phase separation, though it had limited free-flowing behavior.

DOI: 10.26434/chemrxiv-2023-zdt5s

Enhancing Maize Production in Mali: The Role of Fertilizer Microdosing and Mechanization in Improving Yield, Economic Returns, and Reducing Labor Use

Kamkam Woumou, Adama Coulibaly, Jens B. Aune

Maize grain yield increased with NPK microdosing rates up to 93 kg/ha, producing 1029 kg/ha (61.3%) more grain than the control in Mali. A rate of 63 kg NPK/ha matched the yield and economic return of the recommended 100 kg NPK/ha applied in rows. The 78.1 kg NPK/ha rate gave the highest average gross margin and value-cost ratio across two price scenarios. All fertilizer treatments had a value-cost ratio above two, indicating low financial risk even with non-subsidized fertilizer. Manual sowing and microdosing required 11.4 man-days/ha, versus 1.0 man-days/ha for mechanized operations, suggesting farmers will adopt microdosing only if mechanized.

DOI: 10.21203/rs.3.rs-5331059/v1

Microdosing Transdermal Buprenorphine to Transition a Patient off a Higher-Dose Methadone Regimen

Hannan Moses Braun, Kristy L. Blackwood, Jeffrey P. Bratberg et al.

A patient taking high-dose methadone successfully transitioned to buprenorphine using a transdermal microdosing protocol that did not require prior methadone dose tapering and avoided opioid withdrawal symptoms. The protocol included an as-needed full opioid agonist. This case suggests that microinduction can remove the prerequisite of moderate withdrawal typically needed for buprenorphine initiation, though further research is needed to define optimal protocols, especially for patients on methadone or using illicit fentanyl.

DOI: 10.21203/rs.3.rs-1156533/v1

A quantitative exploration of the relationships between regular yoga practice, microdosing psychedelics, wellbeing and personality variables

Stephen Bright, Eyal Gringart, Emily Blatchford et al. preprint

People who microdose psychedelics report similar improvements in psychological wellbeing, openness, and absorption as people who practice yoga. In a survey of 339 adults, both the yoga-only and microdose-only groups scored higher on wellbeing and absorption than a control group. Those who both microdosed and practiced yoga had the lowest depression scores (lower than the microdose-only group) and the lowest anxiety scores (lower than the yoga-only group), and they also had the highest absorption scores. The control group scored significantly lower on openness than all other groups. The findings suggest that microdosing and yoga may have comparable subjective effects and that combining both could be especially beneficial, although the study cannot establish causation.

DOI: 10.31219/osf.io/zkpxe

3D Microfluidic Channel Development for a Microdosing System

Ana C. Romo-Cardenas, Carlos A. Ruiz-Delgado, Paulo C. Calvo et al. preprint

A passively operated microfluidic device fabricated using 3D-printed templates enables insulin microdosing. The system includes a microvalve with a spiral trajectory and four outlet channels that align with a 10 mm x 15 mm matrix of 25 microchannels, each 770 µm in internal diameter. It delivers a dose of 2.3 mL in 6 minutes. The design enhances fluid dynamics without affecting insulin stability and allows the use of Humalog insulin in tropical climates up to 30°C without refrigeration for 28 days. The approach can be adapted for microdosing other drugs.

DOI: 10.20944/preprints202404.0902.v1

Data from Is It Time to Advance the Chemoprevention of Environmental Carcinogenesis with Microdosing Trials?

Thomas W. Kensler, John D. Groopman

This perspective discusses using microdosing with environmental carcinogens to speed up the testing and improvement of chemopreventive treatments. It covers the need for preventing cancer caused by environmental factors, the design of microdosing (phase 0) trials, the technologies needed for such studies, and ethical issues. It also reviews lessons learned from microdosing research so far.

DOI: 10.1158/1940-6207.c.6543726

Microdosing Is More Than Placebo In Some Individuals: A Critical Re-examination of ‘Self-blinding citizen science to explore psychedelic microdosing’

Gregory preprint

A reanalysis of Szigeti et al.'s (2021) self-blinding citizen science study on psychedelic microdosing partially supports the original conclusions but identifies specific conditions where microdosing produces positive effects compared to placebo. Positive effects were found for participants who received both placebo and treatment during their trial (affective benefits), felt some level of intoxication, correctly identified placebo from treatment, and had at least mild depression. The findings add to evidence that certain benefits may exist for psychedelic microdosing under particular circumstances.

DOI: 10.31219/osf.io/sf75q

Sex-dependent effects of psychedelics: review of evidence from rodent models

Frontiers in Psychiatry July 15, 2026 Rafał Marecki, Wiktoria Zaniewska, Adam Hamed et al.

Classic psychedelics such as psilocybin, LSD, DMT, 5-MeO-DMT, mescaline, and DOI work primarily by activating 5-HT2A receptors, causing widespread brain and behavior changes relevant to psychiatric research. Evidence from rodent studies shows that these effects differ by sex across pharmacokinetics, physiology, neuroplasticity, behavior, and disease models. Females often show stronger or qualitatively distinct behavioral responses, including head twitch, locomotor activity, prepulse inhibition, stress reactivity, and social behavior, with ovarian cycle phase further modulating some effects. Disease model studies also find sex-dependent outcomes, such as psilocybin's effects on alcohol consumption and DMT microdosing on mood and neuroplasticity. The review concludes that sex is a critical biological variable shaping psychedelic effects in rodents, and integrating sex-specific analyses is essential for improving translational validity and guiding clinical applications.

DOI: 10.3389/fpsyt.2026.1824073 Serotonergic Prepulse inhibition Anhedonia Schizophrenia object-oriented programming +12

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Chronic microdosing of psilocin (0.05 or 0.075 mg/kg) in adult male Wistar rats over five weeks did not alter locomotor activity, depressive-like behavior, sociability, or novelty seeking, and did not increase cell proliferation in the dentate gyrus of the hippocampus. A small anxiogenic effect was detected in the Elevated Plus Maze. The findings suggest that, under this dosing schedule, psilocin microdosing produces limited behavioral effects and does not enhance hippocampal progenitor proliferation.

DOI: 10.1016/j.pbb.2026.174231 Full text Anxiety Depression Behavioral testing Hippocampal neurogenesis +3

Clinical trials

All Microdosing trials →